Regeneron (NASDAQ:REGN) and non-U.S. commercialization partner Bayer (NASDAQOTH:BAYRY) got some great news last week, when the European Committee for Medicinal Products for Human Use (CHMP) recommended its eye drug Eylea for approval for the treatment of visual impairment due to diabetic macular edema (DME). It's a big potential follow-on indication (as many as 6.2 million people) for a drug that's already been approved and made just under $2 billion in sales last year.
This is a drug that analysts estimate could bring in as much as $4.7 billion annually in peak sales for Regeneron.
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson lay out Regeneron's exciting prospects for this drug.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
GM Proved Doubters Wrong in 2017 With a Strong Crossover Lineup
GM surprised the market when it announced strong guidance thanks to a revamped line of crossovers and SUVs. Better still, it delivered on the promises.
Ford's Behind-the-Scenes Focus on Data
Ford’s recent partnerships and small-scale tests could bode well for the future.
Ford's Tumultuous 2017
Ford’s stock languished behind GM throughout 2017. Will 2018 be a turnaround year?